Atlas Trials

Alumis Inc

13 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Alumis Inc

RecordFirmDate
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage (NCT06952634)Alumis Inc2025-04-29
An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function (NCT06962774)Alumis Inc2025-04-23
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis (NCT06846541)Alumis Inc2025-01-08
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (NCT06588738)Alumis Inc2024-08-20
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis (NCT06586112)Alumis Inc2024-07-25
An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001 (NCT07378579)Alumis Inc2024-06-21
An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005 (NCT07442149)Alumis Inc2024-04-22
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus (NCT05966480)Alumis Inc2023-06-26
POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU (NCT05953688)Alumis Inc2023-06-14
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis (NCT05739435)Alumis Inc2023-01-17
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis (NCT05600036)Alumis Inc2022-09-27
Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants (NCT05431634)Alumis Inc2022-05-12
Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants (NCT05330858)Alumis Inc2022-03-17

Track Alumis Inc automatically

Every clearance here is in the API, with alerts when new ones post.